To provide an overview of the opportunities and challenges associated with the use of circulating tumor DNA (ctDNA) in sarcoma for monitoring treatment response, detecting minimal residual disease, and informing therapy adjustments.
Approach:
Overview of ctDNA: Discusses the role of ctDNA in other solid tumors to frame potential clinical applications in sarcoma.
Sarcoma Genomics: Provides a high-level overview of sarcoma genomics and the technological challenges in applying ctDNA across major disease subtypes.
Current State of ctDNA in Sarcomas: Summarizes the current literature on ctDNA in soft tissue and bone sarcomas, focusing on specific subtypes.
Future Directions: Identifies areas for further development in leveraging ctDNA in sarcoma.
Key Findings:
ctDNA levels correlate with tumor dynamics during treatment and recurrence across various tumor types.
Only a limited number of contemporary studies have included sarcoma patients, highlighting the need for more research.
Current support for ctDNA in sarcoma is largely from small, retrospective studies.
Interpretation:
The existing literature suggests that ctDNA could play a role in monitoring treatment response and disease recurrence in sarcoma, although current support is largely from small, retrospective studies.
Limitations:
The rarity and genomic variability of sarcoma subtypes limit the applicability of ctDNA findings.
Current studies are primarily small and retrospective, necessitating further research.
Conclusion:
ctDNA in sarcoma remains in early investigational stages, with potential applications for clinical decision-making.
